Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy |
Oguz, Arzu
(Baskent University, Medical Oncology Department)
Aykas, Fatma (Kayseri Education and Research Hospital, Internal Medicine Clinic) Unal, Dilek (Kayseri Education and Research Hospital, Radiation Oncology Clinic) Karahan, Samet (Kayseri Education and Research Hospital, Internal Medicine Clinic) Uslu, Emine (Kayseri Education and Research Hospital, Internal Medicine Clinic) Basak, Mustafa (Kayseri Education and Research Hospital, Internal Medicine Clinic) Karaman, Ahmet (Kayseri Education and Research Hospital, Gastroenterology Clinic) |
1 | Yeo W, Ho WM, Hui P, et al (2004). Use of lamuvidine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat, 88, 209-15. DOI ScienceOn |
2 | Yazici Y, Demir N, Cinarka H, Yilmaz H, Altintas N (2010). Seroprevalences of HBV, HCV and HIV among healthcare workers of Trabzon Chest Diseases Hospital. Turkish Bull Hyg Experiment Biol, 67, 27-32. |
3 | Yeo W, Chan PK, Zhong S, et al (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 62, 299-307. DOI |
4 | Yeo W, Chan PK, Hui P, et al (2003). Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol, 70, 553-61. DOI ScienceOn |
5 | Yeo W, Johnson PJ (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43, 209-20. DOI ScienceOn |
6 | Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM (1998). Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer, 83, 1224-30. DOI |
7 | Persico M, De Marino F, Russo GD, et al (2002). Efficacy of lamuvidine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood, 99, 724-5. DOI ScienceOn |
8 | Soh LT, Ang PT, Sng I, Chua EJ, Ong YW (1992). Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer, 28, 1338-9. DOI ScienceOn |
9 | Mehmet D, Meliksah E, Serif Y, et al (2005). Prevalence of hepatitis B infection in the southeast region of Turkey: comparison of risk factors in rural and urban areas. Jpn J Infect Dis, 58, 15-9. |
10 | Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996). Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer, 78, 2210-5. DOI |
11 | Steinberg JL, Yeo W, Zhong S, et al (2000). Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: procore/core mutations may play an important role. J Med Virol, 60, 249-55. DOI |
12 | Utkan G, Azap A, Muallaoglu S, et al (2006). Hepatitis B and C in cancer patients: case-control study. Int J Hematol Oncol, 16, 103-7. |
13 | Uzun K, Alici S, Ozbay B, Gencer M, Irmak H (2002). The incidence of hepatitis C virus in patients with lung cancer. Turkish Respiratory J, 3, 91-3. |
14 | Vento S, Cainelli F, Mirandola F, et al (1996). Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet, 347, 92-3. DOI ScienceOn |
15 | Kohrt HE, Ouyang DL, Keeffe EB (2006). Systematic review: lamuvidine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther, 24, 1003-16. DOI ScienceOn |
16 | Kose S, Olmezoglu A, Gozaydin A, Ece G (2011). Seroprevalence of Hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr, 29, 652-5. |
17 | Hwang YY, Liang RH (2010). Hepatitis C in haematological patients. Hepat Res Treat, 2010, 961359. |
18 | Kanamori H, Fukawa H, Maruta A, et al (1992). Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci, 303, 109-11. DOI ScienceOn |
19 | Kumagai K, Takagi T, Nakamura S, et al (1997). Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol, 8, 107-9. DOI ScienceOn |
20 | Lau GK, Yiu HH, Fong DY, et al (2003). Early is superior to deferred preemptive lamuvidine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterol, 125, 1742-9. DOI ScienceOn |
21 | Lavanchy D (2004). Hepatitis B virus epidemiology, disaese burden, treatment and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107. DOI ScienceOn |
22 | Long M, Jia W, Li S, et al (2011). A single center, prospective and randomized controlled study: Can the prophylactic use of lamuvidine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat, 127, 705-12. DOI |
23 | Loomba R, Rowley A, Wesley R, et al (2008). Systematic review: the effect of preventive lamuvidine on Hepatitis B reactivation during chemotherapy. Ann Intern Med, 148, 519-28. DOI ScienceOn |
24 | Cainelli F, Longhi MS, Concia E, Vento S (2001). Failure of lamuvidine therapy for chemotherapy induced reactivation of hepatitis. Am J Gastroenterol, 96, 1651-2. DOI |
25 | Besson C, Canioni D, Lepage E, et al (2006). Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol, 24, 953-60. DOI ScienceOn |
26 | Alagozlu H, Ozdemir O, Koksal B, Yilmaz A, Coskun M (2013). Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. Asian Pac J Cancer Prev, 14, 5489-94. 과학기술학회마을 DOI ScienceOn |
27 | Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999). Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer, 81, 69-74. DOI |
28 | Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN (1998). Successful treatment with lamuvidine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol, 9, 385-7. DOI ScienceOn |
29 | Custer B, Sullivan SD, Hazlet TK, et al (2004). Global epidemiology of hepatitis B virus. J Clin Gastroenterol, 38, 158-68. DOI ScienceOn |
30 | European Association for the Study of the Liver (2011). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol, 55, 245-64. DOI ScienceOn |
31 | Gurol E, Saban C, Oral O, Cigdem A, Armagan A (2006). Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol, 21, 299-305. DOI |
32 | Arcaini L, Merli M, Passamonti F, et al (2010). Impact of treatment related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol, 85, 46-50. |
33 | Ter Borg F, Smorenburg S, de Man RA, et al (1998). Recovery from life threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamuvidine therapy. Dig Dis Sci, 43, 2267-70. DOI ScienceOn |